CAGRILINTIDE REGULATORY STATUS
Is Cagrilintide FDA-Approved?
Regulatory Status and Clinical Development
Is cagrilintide FDA-approved? No. Cagrilintide is an investigational drug still moving through clinical development — it has not been approved by the FDA for any use.
Cagrilintide is a long-acting amylin analog developed by Novo Nordisk, mainly studied for weight management, including in a combination product with semaglutide called CagriSema.
What Is Cagrilintide?
Cagrilintide mimics amylin, a hormone the body naturally releases with insulin that influences appetite and fullness. It works through a different pathway than the GLP-1 medications that dominate current weight-management treatment.
Source: Novo Nordisk clinical program disclosures; peer-reviewed REDEFINE trial reporting.
What "Investigational" Means
An investigational compound is one still being evaluated in the drug-development and review process. Findings, even from large phase 3 trials, are part of an ongoing evaluation and do not establish FDA approval. Outside of an authorized clinical trial, cagrilintide is not an approved prescription product.
Research-Labeled Cagrilintide
A research-labeled cagrilintide vial is not an approved medication and is not the manufacturer's clinical-trial product. It has not been reviewed by the FDA for identity, purity, potency, sterility, or effectiveness.
Source: FDA questions and answers about drug compounding.
Frequently Asked Questions
Is cagrilintide the same as CagriSema?
No. Cagrilintide is one component; CagriSema is a combination of cagrilintide and semaglutide. Neither is FDA-approved at the time of writing.
Can I buy FDA-approved cagrilintide?
No. It is investigational; there is no approved cagrilintide product to purchase.
The Bottom Line
Cagrilintide is an investigational amylin analog with promising clinical-trial data for weight management, but it is not FDA-approved, and neither is the CagriSema combination at the time of writing.
This article is for general educational purposes only. It is not medical advice and should not be used to diagnose, treat, or make decisions about any health condition or medication.
Primary Sources
- Novo Nordisk REDEFINE 1 phase 3 trial results
- Novo Nordisk regulatory filing announcements (CagriSema)
- FDA Compounding Q&A
Wellness should feel clear, personal, and supported.
Start with education, ask the right questions, and take the next step with confidence.
Get in touch →